Search

Your search keyword '"Kim, Jeri"' showing total 514 results

Search Constraints

Start Over You searched for: Author "Kim, Jeri" Remove constraint Author: "Kim, Jeri"
514 results on '"Kim, Jeri"'

Search Results

1. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

2. Genetic factors associated with prostate cancer conversion from active surveillance to treatment

5. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

6. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

8. Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone‐sensitive prostate cancer.

11. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

12. Observational and genetic associations between cardiorespiratory fitness and cancer : a UK Biobank and international consortia study

13. Observational and genetic associations between cardiorespiratory fitness and cancer:a UK Biobank and international consortia study

14. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

15. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

16. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer

17. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes

23. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer

24. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

25. Genitourinary Cancer Survivorship Management

27. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

28. Treatment Patterns, Clinical Outcomes, Healthcare Resource Utilization and Costs in Older Patients with Metastatic Castration-Resistant Prostate Cancer in the United States: An analysis of SEER-Medicare data

29. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

30. Shared heritability and functional enrichment across six solid cancers

31. Supplementary Table S2 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

32. Supplementary Figure S4 from Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

33. Table S4 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

34. Figure S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer

36. Supplementary Figure 1 from Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

37. Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

40. Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).

41. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

46. Germline variation at 8q24 and prostate cancer risk in men of European ancestry

48. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Catalog

Books, media, physical & digital resources